Pérez, K, Santamariña-Rubio, E, López, MJ, Artazcoz, L, Ferrando, J, Pastor, C, Hyder, AA, Borrell, C. 25 years of providing evidence on road safety interventions at the city level. Frontiers in Public Health. 2025; 12DOI:10.3389/fpubh.2024.1463878. PMID:39989864. IF:3.400(Q1/2D).

Sanz-Mas, M, Continente, X, Marí-Dell'Olmo, M, López, MJ. Community Use and Perceptions of Climate Shelters in Schoolyards in Barcelona. International Journal of Public Health. 2025; 70DOI:10.3389/ijph.2025.1608083. PMID:39990015. IF:2.400(Q2/4D).

Bosch, G, Queralt, A, Valero, N, Lleó, T, Portolés, C, Vargas-Leguas, H, Parra, E, Gonzalez, R, Rius, C, Gómez-Gutiérrez, A. Sprinkler irrigation of urban sport fields as a potential source of Legionella. Archives of Environmental & Occupational Health. 2025; 80(1-2)DOI:10.1080/19338244.2025.2451903. PMID:39874031. IF:0.900(Q4/9D).

Rico-Pereira, M, Muñoz-Hernández, F. Anterior clinoid process metastasis with sudden loss of vision: role of emergency optic nerve decompression. Egyptian Journal Of Neurosurgery. 2025; 40(1)DOI:10.1186/s41984-025-00371-3. PMID:. IF:(Q/D).

Bastos-Oreiro, M, Iacoboni, G, Garcés, VN, Caballero, AC, Martínez, N, Delgado, J, Balaguer, A, Kwon, M, de Villambrosia, S, Hernani, R, Jimenez-Ubieto, A, Bailen, R, Zaberio, I, García-Sancho, A, Barba, P. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Hemasphere. 2025; 9(2)DOI:10.1002/hem3.70077. PMID:39906687. IF:14.600(Q1/1D).

Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer. 2025; 13(2)DOI:10.1136/jitc-2024-010674. PMID:39904562. IF:10.600(Q1/1D).